Hypertrophy

Hypertrophy research - key publications using PLN antibodies

Please rate these pages to support our infographic project:
Get free premium widgets for your blog and website.

References
  1. Boknik, P. et al. 2000. Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol. 362(3), pp.222-31.
  2. Boknik, P. et al. 2001. Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovascular Research. 51(4), pp.717-728.
  3. Bye, A. et al. 2008. Carbon monoxide levels experienced by heavy smokers impair aerobic capacity and cardiac contractility and induce pathological hypertrophy. Inhalation Toxicology. 20(7), pp.635-646.
  4. Chakraborty, A. et al. 2014. Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor. PLoS One. 9(8), pe104338.
  5. Chen, X.W. et al. 2011. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology. 50(3), pp.460-470.
  6. Denipote, F. et al. 2011. Influence of Taurine on Cardiac Remodeling Induced by Tobacco Smoke Exposure. Cellular Physiology and Biochemistry. 27(3-4), pp.291-298.
  7. Guinto, P.J. et al. 2009. Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol. 297(2), pp.H614-26.
  8. Song, L.S. et al. 2005. Paradoxical cellular Ca2+ signaling in severe but compensated canine left ventricular hypertrophy. Circulation Research. 97(5), pp.457-464.

Back to main infographic.

About us
meet the team
Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.

Follow us on social

Contact us
We look forward to providing your favourite antibodies and kits
gender and body
×
×

Cart